Sandoz enters US generic injectables market
Sandoz' acquisition of Canadian generic manufacturer Sabex will give the firm entry into the U.S. sterile injectable market, the company said June 7. The injectable medicines Infufer (iron dextran) and hydromorphone are Sabex' leading U.S. products. The company makes a total of 89 Canadian generic molecules in its FDA-approved facilities. The deal also allows Sandoz to bring its solid oral generics to the Canadian market. The $565 mil. cash transaction is expected to close in July. Sandoz plans to retain the entire Sabex management team...
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.
US FDA proposed increasing staffing and resources for both programs during the next user fee program cycle, but industry representatives did not believe it necessary.